• Home
  •  / Medicxi Ventures
Medicxi Ventures

Medicxi Ventures


£6.3 M

FY, 2018

Medicxi Ventures Summary

Company summary

We invest in the life sciences, with particular focus on therapeutics. We are equally comfortable investing at a very early stage of drug development, when candidate drugs have just been discovered and are entering preclinical development, as at later stages. We back scientists that we believe can become future industry leaders: smart and insightful, driven by clear product vision, comfortable in unchartered territory, sharp, independent decision makers, ready to change direction when the data speaks. In short, we aspire to back entrepreneurs.We recognise that drug discovery is difficult and firmly believe that only molecules that are supported by the strongest conviction of key scientists deserve financial backing. The absence of reasons to stop a drug development program (“red flags”) should not, by itself, be a justification for moving a program forward; strong conviction is a much more appropriate decision-making tool in early-stage R&D. We believe that simply relying on statistical considerations as a predictor for success in drug discovery is not a sustainable strategy.
Greater London, GB | view all locations
Cybersecurity rating

Key people

LocationsView all

3 locations detected

  • Greater London, England HQ

    United Kingdom

    25 Great Pulteney St

  • Saint Helier, St Helier


    44 Esplanade

  • Genève, GE


    Cr de Rive 10

Medicxi Ventures Financials

Summary financials

Revenue (FY, 2018)
Net income (FY, 2018)
Cash (FY, 2018)
EBIT (FY, 2018)

Footer menu